Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1951]

Sacituzumab govitecan plus pembrolizumab improves outcomes beyond progression...

Dr Kevin Kalinsky - Winship Cancer Institute, Atlanta, USA

Sacituzumab govitecan plus pembrolizumab improves outcomes beyond progression in PD-L1-positive metastatic triple-negative breas ( Dr Kevin Kalinsky - Winship Cancer Institute, Atlanta, USA )

Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk...

Dr Matteo S. Carlino - Westmead Hospital and Melanoma Institute Australia...

Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk melanoma ( Dr Matteo S. Carlino - Westmead Hospital and Melanoma Institute Australia, Sydney, Australia )

Tarlatamab in SCLC shows consistent survival and low immune toxicity across age...

Dr Raymart Macasaet - Monmouth Medical Center, Long Branch, USA

Tarlatamab in SCLC shows consistent survival and low immune toxicity across age groups ( Dr Raymart Macasaet - Monmouth Medical Center, Long Branch, USA )

Adjuvant avelumab reduces relapse risk in stage III Merkel cell carcinoma

Dr Shailender Bhatia - Fred Hutchinson Cancer Center, Seattle, USA

Adjuvant avelumab reduces relapse risk in stage III Merkel cell carcinoma ( Dr Shailender Bhatia - Fred Hutchinson Cancer Center, Seattle, USA )

Olaparib plus pembrolizumab improves response but not PFS in BRCA-mutant...

Dr Vincent Chung - City of Hope, Duarte, USA

Olaparib plus pembrolizumab improves response but not PFS in BRCA-mutant pancreatic cancer ( Dr Vincent Chung - City of Hope, Duarte, USA )

Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R...

Dr Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma ( Dr Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )

ASCO 2026: Latest updates in mRCC

Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke

ASCO 2026: Latest updates in mRCC ( Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke )

Tafasitamab plus lenalidomide and R-CHOP delays disease progression in...

Dr Georg Lenz - University Hospital Münster, Münster, Germany

Tafasitamab plus lenalidomide and R-CHOP delays disease progression in aggressive B-cell lymphomas ( Dr Georg Lenz - University Hospital Münster, Münster, Germany )

Adagloxad simolenin plus OBI-821 shows no survival benefit compared to standard...

Dr Hope Rugo - City of Hope, Duarte, USA

Adagloxad simolenin plus OBI-821 shows no survival benefit compared to standard of care in triple-negative breast cancer ( Dr Hope Rugo - City of Hope, Duarte, USA )

Neoadjuvant chemoradiotherapy plus sintilimab improves pCR in resectable...

Dr Xue-Feng Leng - Sichuan Cancer Hospital & Institute, Chengdu, China

Neoadjuvant chemoradiotherapy plus sintilimab improves pCR in resectable locally advanced oesophageal squamous cell carcinoma ( Dr Xue-Feng Leng - Sichuan Cancer Hospital & Institute, Chengdu, China )

ASCO 2026: Breast cancer overview

Dr Hope Rugo - City of Hope, Duarte, USA

ASCO 2026: Breast cancer overview ( Dr Hope Rugo - City of Hope, Duarte, USA )

Combination therapeutic strategies for aRCC patients with bone metastases

Prof Stéphane Oudard and Dr Stefanie Zschäbitz

Combination therapeutic strategies for aRCC patients with bone metastases ( Prof Stéphane Oudard and Dr Stefanie Zschäbitz )

More from ecancer